Hematologic Malignancy
Myelodysplastic Syndrome
CI-CAN-00001247MDN · MDSExplore in graph →
Hematologic336 active trials3 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001247MDN · MDSExplore in graph →
Clinical trials
1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (307)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00113828 | Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies | terminated | Phase 2 | 5 | Massachusetts General HospitalOTHER | 1 | Mar 15, 2018 | clinicaltrials |
| NCT02269579 | Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment | withdrawn | Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Mar 14, 2018 |
| clinicaltrials |
| NCT02198482 | Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | terminated | Phase 2 | 6 | University of UlmOTHER | 1 | Feb 28, 2018 | clinicaltrials |
| NCT00852709 | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias(POE07-01) | terminated | Phase 1 | 35 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Feb 15, 2018 | clinicaltrials |
| NCT00064376 | Paricalcitol in Treating Patients With Myelodysplastic Syndrome | completed | Phase 2 | — | Cedars-Sinai Medical CenterOTHER | 1 | Jan 29, 2018 | clinicaltrials |
| NCT00281814 | Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant | completed | — | 36 | The Cleveland ClinicOTHER | 1 | Jan 26, 2018 | clinicaltrials |
| NCT01491958 | Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation | completed | Phase 2 | 40 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT03408210 | Total Marrow and Lymphoid Irradiation and Chemotherapy for Myelodysplastic Syndrome or Acute Leukemia | unknown | N/A | 191 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT00875693 | A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML) | completed | Phase 1 | 47 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT02294552 | Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT | completed | Phase 2 | 200 | Ivan S MoiseevOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT00908167 | Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies | completed | Phase 1 | 44 | St. Jude Children's Research HospitalOTHER | 1 | Jan 12, 2018 | clinicaltrials |
| NCT00619645 | Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers | completed | Phase 2 | 8 | University of California, DavisOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT00854646 | Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | completed | Phase 1 | 22 | Traws Pharma, Inc.INDUSTRY | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01564277 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT01442714 | Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS | terminated | Phase 2 | 33 | Stanford UniversityOTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT00445744 | Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | completed | N/A | 52 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2018 | clinicaltrials |
| NCT00295880 | Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer | terminated | Phase 1 / Phase 2 | 12 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Dec 28, 2017 | clinicaltrials |
| NCT00354172 | Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers. | terminated | Phase 2 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00392782 | Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease | terminated | Phase 2 | 24 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00602446 | Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant | terminated | Phase 2 | 4 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00818649 | Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia | terminated | Phase 2 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00963872 | Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer | terminated | Phase 1 / Phase 2 | 31 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT02308761 | A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome | completed | Phase 1 | 26 | Hoffmann-La RocheINDUSTRY | 1 | Dec 11, 2017 | clinicaltrials |
| NCT03091933 | Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)(GLIDE) | unknown | Phase 1 / Phase 2 | 20 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00176839 | Stem Cell Transplantation for Hematological Malignancies | terminated | Phase 2 / Phase 3 | 11 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00556452 | Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen | completed | Phase 1 / Phase 2 | 46 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00686556 | Total Marrow Irradiation for Refractory Acute Leukemia | completed | Phase 1 | 12 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT01207076 | AHN-12 Biodistribution in Advanced Leukemia | terminated | Phase 1 | 8 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT02765997 | StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00899795 | Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers | completed | — | 35 | OHSU Knight Cancer InstituteOTHER | 1 | Dec 4, 2017 | clinicaltrials |
| NCT00376519 | Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases | terminated | Phase 1 | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00530218 | Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant | completed | Phase 2 | 61 | City of Hope Medical CenterOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00602693 | T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | completed | Phase 1 | 41 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01163201 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00167167 | Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia | completed | N/A | 40 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00290628 | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | terminated | N/A | 43 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00290641 | Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer | completed | N/A | 68 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00365287 | Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer | completed | Phase 1 / Phase 2 | 148 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT00618696 | Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia | terminated | Phase 1 | 4 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00725062 | Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | terminated | Phase 1 | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT03356080 | DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess | unknown | Phase 2 | 50 | Shanghai Tong Ren HospitalOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT01110473 | ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies | completed | Phase 1 | 52 | AbbVie (prior sponsor, Abbott)INDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT01831232 | Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | N/A | 24 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00903422 | Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS) | completed | Phase 1 | 98 | GlaxoSmithKlineINDUSTRY | 11 | Nov 13, 2017 | clinicaltrials |
| NCT00964821 | Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant | completed | — | 459 | City of Hope Medical CenterOTHER | 1 | Nov 7, 2017 | clinicaltrials |
| NCT02433483 | Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients | terminated | Phase 2 | 4 | St. Jude Children's Research HospitalOTHER | 1 | Nov 1, 2017 | clinicaltrials |
| NCT01101880 | Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm | completed | Phase 2 | 50 | University of WashingtonOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT00301951 | Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer | completed | Phase 1 | 7 | University of California, San FranciscoOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT00006239 | Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 29, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Mar 15, 2018source: clinicaltrials